The multidrug-resistant tuberculosis threat: old problems and new solutions.

With more than 1 million deaths and 9 million estimated incident cases in 2013 tuberculosis represents one of the top clinical and public health priorities worldwide (1).

[1]  G. Sotgiu,et al.  Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience , 2015, European Respiratory Journal.

[2]  P. Mohapatra.  Bedaquiline: finding the pores on the pot , 2015, European Respiratory Journal.

[3]  G. Sotgiu,et al.  Untreatable tuberculosis: is surgery the answer? , 2015, European Respiratory Journal.

[4]  E. Pontali,et al.  Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios , 2015, European Respiratory Journal.

[5]  F. Blasi,et al.  Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation , 2014, European Respiratory Journal.

[6]  Eduardo Gotuzzo,et al.  Multidrug-resistant tuberculosis and culture conversion with bedaquiline. , 2014, The New England journal of medicine.

[7]  A. Benedetti,et al.  Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster , 2014, European Respiratory Journal.

[8]  F. Blasi,et al.  ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use , 2014, European Respiratory Journal.

[9]  G. Sotgiu,et al.  Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? , 2013, European Respiratory Journal.

[10]  Simon Tiberi,et al.  Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use , 2013, European Respiratory Journal.

[11]  A. Spanevello,et al.  Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence , 2013, European Respiratory Journal.

[12]  A. Diacon,et al.  Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis , 2013, Antimicrobial Agents and Chemotherapy.

[13]  K. Floyd,et al.  Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert®MTB/RIF Weyer, , 2013 .

[14]  T. Holtz,et al.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes , 2012, European Respiratory Journal.

[15]  J. Kosterink,et al.  Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis , 2012, European Respiratory Journal.

[16]  D. Follmann,et al.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis. , 2012, The New England journal of medicine.

[17]  Sonya S. Shin,et al.  Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis , 2012, European Respiratory Journal.

[18]  V. Leimane,et al.  Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis , 2012, European Respiratory Journal.

[19]  Giovanni Sotgiu,et al.  Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB , 2012, European Respiratory Journal.

[20]  Marcos Burgos,et al.  Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients , 2012, PLoS medicine.

[21]  Gee Young Suh,et al.  Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.

[22]  A. Spanevello,et al.  Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  T. Shim,et al.  Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis , 2012, European Respiratory Journal.

[24]  K. Andries,et al.  Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance , 2012, Antimicrobial Agents and Chemotherapy.

[25]  K. Kliiman,et al.  TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? , 2012, European Respiratory Journal.

[26]  K. Kliiman,et al.  TB and M/XDR-TB infection control in European TB reference centres: the Achilles’ heel? , 2011, European Respiratory Journal.

[27]  A. Skrahina,et al.  Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk , 2011, European Respiratory Journal.

[28]  M. D. Granado,et al.  WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update , 2011, European Respiratory Journal.

[29]  G. Sotgiu,et al.  Extensively drug-resistant tuberculosis: back to the future , 2010, European Respiratory Journal.

[30]  G. Sotgiu,et al.  A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis , 2009, European Respiratory Journal.

[31]  K. Kliiman,et al.  Clinical and operational value of the extensively drug-resistant tuberculosis definition , 2007, European Respiratory Journal.

[32]  M. Matsumoto,et al.  OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice , 2006, PLoS medicine.

[33]  E. Chahine,et al.  Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. , 2014, The Annals of pharmacotherapy.

[34]  The role of surgery in the treatment of pulmonary TB and multidrug- and extensively drug-resistant TB , 2014 .

[35]  V. Venkataramanan,et al.  Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.